CN117177992A - 经修饰的抗tslp抗体 - Google Patents

经修饰的抗tslp抗体 Download PDF

Info

Publication number
CN117177992A
CN117177992A CN202280030029.7A CN202280030029A CN117177992A CN 117177992 A CN117177992 A CN 117177992A CN 202280030029 A CN202280030029 A CN 202280030029A CN 117177992 A CN117177992 A CN 117177992A
Authority
CN
China
Prior art keywords
seq
fragment
tslp
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030029.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·邦达连科
L·史
H·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN117177992A publication Critical patent/CN117177992A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280030029.7A 2021-04-23 2022-04-22 经修饰的抗tslp抗体 Pending CN117177992A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178915P 2021-04-23 2021-04-23
US63/178915 2021-04-23
PCT/US2022/025999 WO2022226342A2 (en) 2021-04-23 2022-04-22 Modified anti-tslp antibodies

Publications (1)

Publication Number Publication Date
CN117177992A true CN117177992A (zh) 2023-12-05

Family

ID=81597885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030029.7A Pending CN117177992A (zh) 2021-04-23 2022-04-22 经修饰的抗tslp抗体

Country Status (14)

Country Link
US (1) US20240182558A1 (enExample)
EP (1) EP4326762A2 (enExample)
JP (1) JP2024516595A (enExample)
KR (1) KR20230175245A (enExample)
CN (1) CN117177992A (enExample)
AR (1) AR125404A1 (enExample)
AU (1) AU2022262006A1 (enExample)
BR (1) BR112023022041A2 (enExample)
CA (1) CA3216700A1 (enExample)
CL (1) CL2023003124A1 (enExample)
IL (1) IL307439A (enExample)
MX (1) MX2023012325A (enExample)
TW (1) TW202304980A (enExample)
WO (1) WO2022226342A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions
EP4647084A1 (en) * 2023-01-06 2025-11-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Method for treating asthma by using tslp antibody
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
IL324470A (en) 2023-05-18 2026-01-01 Medimmune Llc Treatment of corticosteroid-dependent asthma using anti-TSLP antibody
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025265071A1 (en) * 2024-06-21 2025-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US8716451B2 (en) * 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
ES2978396T3 (es) * 2017-08-01 2024-09-11 Amgen Inc Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
US20240182558A1 (en) 2024-06-06
CL2023003124A1 (es) 2024-04-26
TW202304980A (zh) 2023-02-01
WO2022226342A2 (en) 2022-10-27
IL307439A (en) 2023-12-01
AR125404A1 (es) 2023-07-12
CA3216700A1 (en) 2022-10-27
EP4326762A2 (en) 2024-02-28
JP2024516595A (ja) 2024-04-16
WO2022226342A3 (en) 2022-12-01
BR112023022041A2 (pt) 2023-12-26
AU2022262006A1 (en) 2023-10-19
KR20230175245A (ko) 2023-12-29
MX2023012325A (es) 2023-10-30

Similar Documents

Publication Publication Date Title
CN117177992A (zh) 经修饰的抗tslp抗体
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
TWI736515B (zh) 類腫瘤壞死因子之配體１ａ之專一性抗體及其組合物及用途
EP3277722B1 (en) Antibodies to canine interleukin-4 receptor alpha
CA3166949A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
EP3693007A1 (en) Methods for treating crohn's disease using an anti-il23 antibody
US20240190951A1 (en) Anti-tslp antibody compositions and uses thereof
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
KR20200128415A (ko) 중증 천식 치료를 위한 항 cd6 항체
TW201842933A (zh) 使用il-17拮抗劑選擇性治療氣喘的方法
US20240360210A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
US20230365712A1 (en) Notch4 antibodies and uses thereof
WO2024092064A1 (en) Anti-tslp antibody compositions and uses thereof
HK40034614A (en) Methods for treating crohn’s disease using an anti-il23 antibody
CN114555120A (zh) 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination